p21(WAF1/CIP1) expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression

Journal of Clinical Pathology

Volumn 51, Issue 2, 1998, Pages 159-162

  Cheung, A N Y ^a   Shen, D H ^c   Khoo, U S ^a   Wong, L C ^b   Ngan, H Y S ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Gestational trophoblastic disease; Ki67; p21(WAF1 CIP1); p53

Indexed keywords

CYCLIN DEPENDENT KINASE; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CELL CYCLE PARAMETERS; CHORIOCARCINOMA; CLINICAL PATHWAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PATHOLOGY; PLACENTA; PREGNANCY DISORDER; PRIORITY JOURNAL; SUPPRESSOR GENE; SYNCYTIOTROPHOBLAST; TROPHOBLASTIC DISEASE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; METABOLISM; PREGNANCY; TROPHOBLASTIC TUMOR; UTERUS CANCER;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; NEOPLASM PROTEINS; PLACENTA; PREGNANCY; TROPHOBLASTIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 0031596847     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.2.159     Document Type: Article

References (35)

1. Harper JW, Adami GR, Wei N, et al. The p21 cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
2. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993;75:817-25.
3. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
4. Guillot C, Falette N, Paperin MP, et al. p21 (WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene 1997;14:45-52.
5. Steinman RA, Hoffman B, Iro A, et al. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9: 3389-46.
6. Mazur MT, Kurman RJ. Gestational trophoblastic disease. In: Kurman RJ, ed. Blaustein's pathology of female genital tract. New York: Springer-Verlag, 1994:1049-93.
7. Elston CW. Gestational trophoblastic disease. In: Fox H, ed. Haines and Taylor: obstetrical and gynaecological pathology. Edinburgh: Churchill Livingstone, 1997:1597-640.
8. Cheung ANY, Srivastava G, Chung LP, et al. Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J Reprod Med 1994;39:223-7.
9. Cheung ANY, HYS Ngan, Collins RJ, et al. Assessment of cell proliferation in hydatidiform mole using monoclonal antibody MIB1 to Ki-67 antigen. J Clin Pathol 1994;47: 601-4.
10. Ma HK, Wong LC, Ngan HYS The modern management of trophoblastic disease. In: Nonnar J, ed. Recent advances in obstetrics and gynaecology. Edinburgh: Churchill Livingstone, 1990:1-23.
11. Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
12. Gpl in muscle and other terminally differ-entiating cells. Science 1995;267:1024-7.
13. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-21.
14. Fredersdorf S, Milne AW, Hall PA, et al. Characterization of a panel of novel anti-p21 Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21 Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996;148:825-35.
15. Doglioni C, Pelosio P, Laurino L, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adeno-carcinomas of the colon: its relationship with differentiation. J Pathol 1996;179:248-53.
16. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
17. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
18. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995;11:493-504.
19. Johnson M, Dimitrov O, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/ WAF1/p21 RNA in human cells. Mol carcinog 1994;11:59-64.
20. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996;180:122-8.
21. Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996;12:1319-24.
22. DiGiuseppe JA, Redston MS, Yeo CJ, et al. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.
23. Barbareschi M, Caffo O, Doglioni C, et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996;74:208-15.
24. Barboule N, Mazars P, Baldin V, et al. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995;63:611-15.
25. waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki67 immunohistochemistry. Int J Gynecol Pathol 1997;16:149-55.
26. Lin J, Reichner C, Wu X, et al. Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol 1996;16: 1786-93.
27. Shimizu T, Miwa W, Nakamori S, et al. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn J Cancer Res 1996;87:275-8.
28. Heinzel PA, Balaram P, Bernard HU. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 1996;68:420-3.
29. Li YJ, Laurent-Puig P, Salmon RJ, et al. Polymorphism and probable lack of mutation in the WAF1-CIP1 in colorectal cancer. Oncogene 1995;10:599-601.
30. Vidal MJ, Loganzo F Jr, de Oliveira AR, et al. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 1995;5:243-50.
31. Shiohara M, el Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84:3781-4.
32. Boyd PA. Quantitative studies of the normal human placenta from 10 weeks of gestation to term. Early Hum Dev 1984;9:297-307.
33. Cheung ANY, Ngan HYS, Chen WZ, et al. The significance of proliferating cell nuclear antigen in human trophoblastic disease: an immunohistochemical study. Histopathology 1993;22:565-8.
34. El-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21WAF1/CTP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-19
35. Jung JM, Bruner JM, Ruan S, et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 1995; 11:2021-8.